Matthew Gumbleton
2PUBLICATIONS
6CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (2)
Sort by Publication Date:
|Feb 16, 2023
A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE).Matthew Gumbleton, Stephanie Allan, Hannah Conway
|Oct 12, 2017
Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival.Matthew Gumbleton, Raki Sudan, Sandra Fernandes
Pageof 1
